Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
Hong Jun LeeJae Seung LeeHyesung SoJa Kyung YoonJin-Young ChoiHye-Won LeeBeom Kyung KimSeung-Up KimJun Yong ParkSang Hoon AhnDo Young KimPublished in: Yonsei medical journal (2024)
Clinical outcomes of patients treated with nivolumab and regorafenib after sorafenib treatment failure did not differ significantly.
Keyphrases